BAX vs NAGE: fair value comparison
Baxter International Inc. and Niagen Bioscience, Inc. · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, NAGE currently sits closer to the top of our discount ranking. NAGE carries the stronger quality grade.
| BAX | NAGE | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $26.13 | $3.53 |
| 12-month range | $16.78–$28.10 | $3.33–$9.88 |
| Sector rank | #65 of 113 Healthcare | #62 of 113 Healthcare |
| Quality grade | F | C |
| Leverage | Moderate | Low |
| Margin trend | Contracting | — |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Downtrend |
| 52-week position | The top quarter | The bottom quarter |
Full single-stock breakdowns: BAX fair value analysis · NAGE fair value analysis